CHF 68.6
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV
Target Price
The average target price of COPN.SW is 87 and suggests 27% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
